Cell death in response to antimetabolites directed at ribonucleotide reductase and thymidylate synthase

References

• JemalASiegelRWardECancer statistics, 2006CA Cancer J Clin20065610613016514137
   PubMed Web of Science ®Google Scholar
• NiederhuberJEBrennanMFMenckHRThe National Cancer Data Base report on pancreatic cancerCancer199576167116778635074
   PubMed Web of Science ®Google Scholar
• WarshawALFernandez-del CastilloCPancreatic carcinomaN Engl J Med19923264554651732772
   PubMed Web of Science ®Google Scholar
• ColemanMPGattaGVerdecchiaAEUROCARE-3 summary: cancer survival in Europe at the end of the 20th centuryAnn Oncol200314128149
   PubMed Web of Science ®Google Scholar
• Carpelan-HolmstromMNordlingSPukkalaEDoes anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data Finnish Cancer RegistryGut20055438538715710987
   PubMed Web of Science ®Google Scholar
• WagnerMRedaelliCLietzMSeilerCAFriessHBuchlerMWCurative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinomaBr J Surg20049158659415122610
   PubMed Web of Science ®Google Scholar
• AhrendtSAPittHASurgical management of pancreatic cancerOncoogy200216725734
   Google Scholar
• MossRALeeCCurrent and emerging therapies for the treatment of pancreatic cancerOnco Targets Ther2010311112720856847
   PubMed Web of Science ®Google Scholar
• LongleyDBHarkinDPJohnstonPG5-Fluorouracil: mechanisms of action and clinical strategiesNat Rev Cancer2003333033812724731
   PubMed Web of Science ®Google Scholar
• ThomasDMZalcbergJR5-Fluorouracil: a pharmacological paradigm in the use of cytotoxicsClin Exp Pharmacol Physiol1998258878959807659
   PubMed Web of Science ®Google Scholar
• AnderssonRAhoUNilssonBIGemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutionsScand J Gastroenterol20094478278619214867
   PubMed Web of Science ®Google Scholar
• MiniENobiliSCaciagliBLandiniIMazzeiTCellular pharmacology of gemcitabineAnn Oncol200617712
   PubMed Web of Science ®Google Scholar
• GiovannettiEMeyVDanesiRMoscaIDel TaccaMSynergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lineClin Cancer Res2004102936294315131028
   PubMed Web of Science ®Google Scholar
• PoplinEFengYBerlinJPhase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology GroupJ Clin Oncol200927233778378519581537
   PubMed Web of Science ®Google Scholar
• LouvetCLabiancaRHammelPGemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trialJ Clin Oncol200523153509351615908661
   PubMed Web of Science ®Google Scholar
• LouvetCAndreTLledoGGemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II studyJ Clin Oncol2002201512151811896099
   PubMed Web of Science ®Google Scholar
• HungSWModyHRGovindarajanROvercoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challengeCancer Lett2012320213814922425961
   PubMed Web of Science ®Google Scholar
• SrinivasulaSMAshwellJDIAPs: what’s in a name?Mol Cell20083012313518439892
   PubMed Web of Science ®Google Scholar
• AltieriDCSurvivin and IAP proteins in cell-death mechanismsBiochem J201043019920520704571
   PubMed Web of Science ®Google Scholar
• DeverauxQLReedJCIAP family proteins-suppressors of apoptosisGenes Dev1999132392529990849
   PubMed Web of Science ®Google Scholar
• MillerLKAn exegesis of IAPs: salvation and surprises from BIR motifsTrends Cell Biol1999932332810407412
   PubMed Web of Science ®Google Scholar
• DeverauxQLTakahashiRSalvesenGSReedJCX-linked IAP is a direct inhibitor of cell-death proteasesNature19973883003049230442
   PubMed Web of Science ®Google Scholar
• RoyNDeverauxQLTakahashiRSalvesenGSReedJCThe c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspasesEMBO J199716691469259384571
   PubMed Web of Science ®Google Scholar
• EckelmanBPSalvesenGSThe human anti-apoptotic proteins cIAP1 and cIAP2 bind but do not inhibit caspasesJ Biol Chem200628163254326016339151
   PubMed Web of Science ®Google Scholar
• HuSYangXCellular inhibitor of apoptosis 1 and 2 are ubiquitin ligases for the apoptosis inducer Smac/DIABLOJ Biol Chem200327812100551006012525502
   PubMed Web of Science ®Google Scholar
• VerdeciaMAHuangHDutilEKaiserDAHunterTNoelJPStructure of the human anti-apoptotic protein survivin reveals a dimeric arrangementNat Struc Biol20007602608
   PubMedGoogle Scholar
• AltieriDCSurvivin, cancer networks and pathway-directed drug discoveryNat Rev Cancer20088617018075512
   PubMed Web of Science ®Google Scholar
• AltieriDCValidating survivin as a cancer therapeutic targetNat Rev Cancer20033465412509766
   PubMed Web of Science ®Google Scholar
• LiFSurvivin study: what is the next wave?J Cell Physiol200319782912942537
   PubMed Web of Science ®Google Scholar
• LiFAckermannEJBennettCFPleiotropic cell-division defects and apoptosis induced by interference with survivin functionNat Cell Biol1999146146610587640
   PubMed Web of Science ®Google Scholar
• KhanSAspeJRAsumenMGExtracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potentialBr J Cancer20091001073108619293795
   PubMed Web of Science ®Google Scholar
• KhanSJutzyJMSAspeJRMcGregorDWNeidighJWWallNRSurvivin is released from cancer cells via exosomesApoptosis201116111220717727
   PubMed Web of Science ®Google Scholar
• WolfersJLozierARaposoGTumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-primingNat Med20017329730311231627
   PubMed Web of Science ®Google Scholar
• GinestraALa PlacaMDSaladinoFCassaraDNagaseHVittorelliMLThe amount of proteolytic content of vesicles shed by human cancer cell lines correlates with their in vitro invasivenessAnticancer Res1998185A343334379858920
   PubMed Web of Science ®Google Scholar
• GinestraAMiceliDDoloVRomanoFMVittorelliMLMembrane vesicles in ovarian cancer fluids: a new potential markerAnticancer Res1999194C3439344510629632
   PubMed Web of Science ®Google Scholar
• AndreFSchartzNEMovassaghMMalignant effusions and immunogenic tumour-derived exosomesLancet2002360932929530512147373
   PubMed Web of Science ®Google Scholar
• WieckowskiEWhitesideTLHuman tumor-derived vs dendritic cell-derived exosomes have distinct biologic roles and molecular profilesImmunol Res2006361–324725417337785
   PubMed Web of Science ®Google Scholar
• ZitvogelLRegnaultALozierAEradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomesNat Med1998455946009585234
   PubMed Web of Science ®Google Scholar
• KhanSJutzyJMSAspeJRThe application of membrane vesicles for cancer therapyAdvances in Cancer Therapy: Intech201121522011
   Google Scholar
• FuldaSVucicDTargeting IAP proteins for therapeutic intervention in cancerNat Rev Drug Discov201211210912422293567
   PubMed Web of Science ®Google Scholar
• MitaACMitaMMNawrockiSTGilesFJSurvivin: key regulators of mitosis and apoptosis and novel targets for cancer therapeuticsClin Cancer Res2008145000500518698017
   PubMed Web of Science ®Google Scholar
• GallowayNRAspeJRSellersCWallNREnhanced antitumor effect of combined gemcitabine and proton radiation in the treatment of pancreatic cancerPancreas200938778279019506533
   PubMed Web of Science ®Google Scholar
• LauRPrattMAThe opposing roles of cellular inhibitor of apoptosis proteins in cancerISRN Oncol2012201292812022934195
   PubMedGoogle Scholar
• LopesRBGangeswaranRMcNeishIAWangYLemoineNRExpression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapyInt J Cancer2007120112344235217311258
   PubMed Web of Science ®Google Scholar
• ShrikhandeSVKleeffJKayedHSilencing of X-linked inhibitor of apoptosis (XIAP) decreases gemcitabine resistance of pancreatic cancer cellsAnticancer Res2006265A3265327317094439
   PubMed Web of Science ®Google Scholar
• YoonDHShinJSJinDHThe survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2Anticancer Res20123251681168822593446
   PubMed Web of Science ®Google Scholar
• ChromikJSafferthalCServeHFuldaSSmac mimetic primes apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosisCancer Lett2014344110110924184825
   PubMed Web of Science ®Google Scholar
• MiuraKKarasawaHSasakiIcIAP2 as a therapeutic target in colorectal cancer and other malignanciesExpert Opin Ther Targets200913111333134519793002
   PubMed Web of Science ®Google Scholar
• KarasawaHMiuraKFujibuchiWDown-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cellsCancer Sci2009100590391319302291
   PubMed Web of Science ®Google Scholar
• NieuwlandRSturkAWhy do cells release vesicles?Thromb Res2010125
   Web of Science ®Google Scholar
• ValentiRHuberVIeroMFilipazziPParmianiGRivoltiniLTumor-released microvesicles as vehicles of immunosuppressionCancer Res20076772912291517409393
   PubMed Web of Science ®Google Scholar
• AndersonHCMulhallDGarimellaRRole of extracellular membrane vesicles in the pathogenesis of various diseases, including cancer, renal diseases, atherosclerosis, and arthritisLan Invest2010901115491557
   Web of Science ®Google Scholar
• van NielGPorto-CarreiroISimoesSRaposoGExosomes: a common pathway for a specialized functionJ Biochem20061401132116877764
   PubMed Web of Science ®Google Scholar
• MearsRCravenRAHanrahanSProteomic analysis of melanoma-derived exosomes by two-dimensional polyacrylamide gel electrophoresis and mass spectrometryProteomics20044124019403115478216
   PubMed Web of Science ®Google Scholar
• HegmansJPBardMPHemmesAProteomic analysis of exosomes secreted by human mesothelioma cellsAm J Pathol200416451807181515111327
   PubMed Web of Science ®Google Scholar
• IeroMValentiRhuberVTumour-released exosomes and their implications in cancer immunityCell Death Differ2008151808817932500
   PubMed Web of Science ®Google Scholar
• ValenzuelaMMANeidighJWWallNRAntimetabolite treatment for Pancreatic CancerChemotherapy20143317
   Google Scholar